Depo-Provera Lawsuit [October 2026 Update]

The Depo-Provera brain tumor MDL added 464 cases between July and August, increasing from 5,830 to 6,294.

The continued surge follows the court’s efforts to organize one of the fastest-growing pharmaceutical MDLs in the country, while plaintiffs continue filing claims alleging long-term Depo-Provera use caused meningioma brain tumors.

Recent settlement discussions involving a limited group of cases have also increased attention on the litigation.

With more than 6,200 pending lawsuits, the Depo-Provera MDL continues to expand rapidly as discovery and bellwether preparations move forward.

Our attorneys are actively accepting new clients for the Depo-Provera lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera lawsuit instantly.

U.S. District Judge M. Casey Rodgers has approved three new pilot plaintiffs in the Depo-Provera MDL, replacing the original five pilot cases now that a global settlement covers roughly 80% of the more than 6,200 pending claims. 

Both plaintiffs’ counsel and Pfizer requested the substitution, since the original five cases were selected to litigate preemption and general causation issues but are now eligible for the settlement, leaving them unable to serve that purpose ahead of a general causation hearing scheduled for September.

Pfizer agreed to the global settlement in June, structured as a grid-based framework with base values adjusted up or down depending on individual case factors. 

Judge Rodgers called the deal an “excellent outcome,” noting it was reached just 16 months into the litigation without a single court ruling on dispositive issues or a trial. 

The new pilot cases will continue to be actively litigated as the MDL moves toward the September causation hearing.

A new study published on July 2 in JAMA Network Open found that Depo-Provera injections were associated with the highest risk of intracranial meningioma among several progesterone-containing contraceptives and hormone therapies.

Researchers with the Danish Medicines Agency analyzed nationwide health data from more than 25 years and found that women who used Depo-Provera had a 4.5-fold increased risk of developing brain tumors.

The study also identified smaller increases in risk associated with certain oral contraceptives and the Mirena IUD, with researchers reporting that the elevated risk generally declined about five years after stopping progesterone-containing products.

The study was published shortly after Pfizer and plaintiffs representing approximately 5,500 women announced that they had reached a global settlement agreement in the federal Depo-Provera litigation.

Following the announcement, U.S. District Judge M. Casey Rodgers vacated the remaining pretrial and bellwether trial deadlines while the parties worked to finalize the settlement terms.

The Depo-Provera brain tumor MDL added 322 cases between June and July, increasing from 5,508 to 5,830.

The continued growth comes after Pfizer reached an agreement in principle to resolve a group of Depo-Provera lawsuits, marking the first significant settlement development in the litigation.

While the agreement involves only a portion of the pending claims, it could influence future negotiations as the MDL continues to expand.

Despite the early settlement efforts, thousands of Depo-Provera brain tumor lawsuits remain pending as the court moves forward with coordinated discovery and case development.

Our attorneys are actively accepting new clients for the Depo-Provera lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms.

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera lawsuit instantly.

A major development has occurred in the Depo-Provera multidistrict litigation (MDL), where thousands of women have filed lawsuits alleging that prolonged use of Depo-Provera caused them to develop meningioma brain tumors.

In June 2026, the parties informed the court that they had reached an agreement in principle on a global settlement framework, prompting the court to pause certain upcoming litigation deadlines while settlement terms are finalized.

At this stage, the settlement agreement remains confidential.

No average settlement amounts, payout tiers, or individual compensation figures have been publicly announced.

The eligibility criteria and compensation structure are still being finalized and have not yet been released.

TorHoerman Law is still accepting new Depo-Provera cases: women who used Depo-Provera and were later diagnosed with a meningioma brain tumor may still qualify to pursue a claim.

Additional information about the settlement process, eligibility requirements, and potential compensation is expected to become available as the agreement moves toward final approval.

Watch the video below for an overview of the settlement agreement and what it may mean for current and future claimants.

Pfizer and plaintiffs’ leadership have reached an agreement in principle that could resolve a substantial majority of the more than 3,400 lawsuits pending in the federal Depo-Provera multidistrict litigation.

Following the announcement, U.S. District Judge M. Casey Rodgers vacated deadlines in the first bellwether case, which had been scheduled for trial in December 2026.

According to court filings, the proposed agreement would allow eligible plaintiffs in the MDL to resolve their claims through a global settlement program.

The parties are currently working to finalize the terms of the agreement, which remain confidential.

The development comes as the litigation approaches several major milestones, including a closely watched hearing on the admissibility of expert causation testimony.

Judge Rodgers has postponed that hearing from June 24 to July 27 while settlement discussions continue.

The agreement represents a significant step in the litigation and may resolve a large portion of the federal cases alleging that Depo-Provera use contributed to the development of meningioma brain tumors.

Pfizer has denied liability and stated that it will continue defending any remaining claims, including cases pending in state courts.

The federal Depo-Provera multidistrict litigation has grown to more than 6,000 pending lawsuits as courts prepare to evaluate critical expert witness testimony regarding whether long-term use of the contraceptive can cause meningioma brain tumors.

The litigation centers on Daubert challenges, a process where the court determines whether expert witnesses may present scientific opinions linking Depo-Provera to intracranial meningiomas.

These hearings are widely viewed as one of the most important milestones in the litigation because expert causation testimony will likely determine whether claims proceed toward bellwether trials and potential settlement discussions.

The expert witness rulings are expected to have a substantial impact on the future of the litigation. If plaintiffs’ experts are permitted to testify, the cases are likely to advance toward bellwether trials and increased settlement pressure.

If key expert opinions are excluded, large portions of the litigation could face significant legal challenges.

The Eleventh Circuit denied a request by a group of Delaware plaintiffs seeking to block a joint evidentiary hearing involving state and federal Depo-Provera brain tumor litigation, allowing the June 2026 proceedings to move forward.

The dispute centered on a planned joint Daubert hearing where judges overseeing related Depo-Provera cases in Florida, Delaware, and New York will hear arguments regarding the admissibility of expert testimony linking Depo-Provera to meningioma brain tumors.

Delaware plaintiffs argued that their state court cases are not part of the federal multidistrict litigation and that the federal court lacks jurisdiction to effectively conduct merits-related proceedings involving their claims.

The appellate court rejected the challenge, finding the plaintiffs failed to meet the high standard required for a writ of mandamus.

As a result, the coordinated hearing will proceed as scheduled and will address whether expert witnesses may testify regarding scientific evidence linking long-term Depo-Provera use to the development of intracranial meningiomas.

The upcoming Daubert proceedings are particularly significant because expert causation testimony will likely determine whether large numbers of Depo-Provera claims advance toward bellwether trials, settlement discussions, or potential dismissal.

The court’s rulings on expert admissibility could substantially influence the direction of both the federal MDL and parallel state court litigation.

The Depo-Provera brain tumor MDL added 1,739 cases between May and June, surging from 3,769 to 5,508.

The sharp increase follows continued attention on research linking prolonged Depo-Provera use to meningioma brain tumors and comes as the federal court works to organize one of the fastest-growing pharmaceutical MDLs in the country.

With more than 5,500 pending claims, the court is expected to focus on discovery planning and bellwether trial preparations in the coming months.

Our attorneys are actively accepting new clients for the Depo-Provera lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera lawsuit instantly. 

The federal Depo Provera litigation continues to expand to more than 6,000 claimants as judges review challenges to expert testimony that could shape the future of the lawsuits.

Recent court proceedings have focused on Daubert challenges, which determine whether expert witnesses can present scientific opinions to juries during future trials.

The outcome is expected to play a major role in whether the cases move toward bellwether trials and possible settlement negotiations.

No trial dates or settlement agreements have been announced at this time.

The Depo-Provera litigation continues to expand at a rapid pace, with nearly 3,800 lawsuits now pending in the federal MDL involving allegations that the birth control injection caused women to develop meningioma brain tumors.

More than 1,600 new lawsuits were added between February and May 2026 alone, making the Depo-Provera MDL one of the fastest-growing pharmaceutical mass torts currently pending in the U.S. court system.

Women filing claims allege that long-term use of Depo-Provera caused or accelerated the growth of meningiomas, which are tumors that develop in the membranes surrounding the brain and spinal cord.

Although many meningiomas are technically noncancerous, plaintiffs indicate the tumors led to serious complications including seizures, vision problems, cognitive impairment and invasive brain surgeries.

A major focus of the litigation now centers on allegations that Pfizer may have known about potential tumor risks tied to medroxyprogesterone acetate, the active ingredient in Depo-Provera, as far back as 1983.

Plaintiffs argue women and the medical community were not adequately warned about those risks for decades, despite growing scientific concerns surrounding hormone-sensitive tumors.

The lawsuits also highlight that Pfizer did not add a meningioma warning to the Depo-Provera label until late 2025, long after many plaintiffs say they had already developed tumors following years of injections.

At the same time, Pfizer continues to aggressively defend the litigation by arguing that many claims should be dismissed under federal preemption principles.

The company maintains that it could not independently add stronger warning labels without FDA approval, which it says may shield it from certain state-law failure-to-warn claims.

The outcome of those legal arguments could play a major role in shaping the future of the litigation as the parties continue preparing for upcoming bellwether trials.

Attorneys are also increasingly focused on whether women who used Depo-Provera for extended periods may face higher meningioma risks tied to cumulative exposure over time.

With filings continuing to surge nationwide, the Depo-Provera MDL is expected to remain one of the most closely watched pharmaceutical litigations moving forward.

A newly filed lawsuit has been added to the growing Depo-Provera multidistrict litigation, with the plaintiff alleging that prolonged use of the contraceptive injection caused her to develop an intracranial meningioma after years of treatment.

According to the complaint, the plaintiff began experiencing persistent and worsening headaches before ultimately being diagnosed with a brain tumor.

The lawsuit alleges the tumor caused significant neurological symptoms and required ongoing medical monitoring and treatment.

The case claims manufacturers failed to adequately warn patients and healthcare providers about research linking long-term exposure to medroxyprogesterone acetate, the active ingredient in Depo-Provera, to an increased risk of meningioma brain tumors.

The plaintiff alleges she would have avoided or discontinued the injections had proper warnings been provided earlier.

The lawsuit has now joined the broader Depo-Provera MDL, where plaintiffs are similarly alleging failure to warn, defective design, and inadequate disclosure of neurological risks associated with long-term use of the drug.

The Depo-Provera brain tumor MDL added 279 cases between April and May, increasing from 3,490 to 3,769 cases pending.

The continued rise shows sustained filing momentum tied to meningioma injury claims.

Currently, the litigation is inching toward a causation hearing set for late June 2026, which will further analyze the links between Depo-Provera usage and the risk of meningioma brain tumors.

Our attorneys are actively accepting new clients for the Depo-Provera lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera lawsuit instantly.

Federal litigation involving Depo-Provera continues to grow following the addition of a new FDA-approved warning addressing the risk of meningioma brain tumors associated with prolonged use of the contraceptive injection.

The labeling update, approved in late 2025, is now central to claims that patients and prescribing physicians were not adequately informed of potential risks.

Plaintiffs allege that Pfizer failed to provide timely warnings about a connection between long-term use of Depo-Provera and the development of meningiomas.

The recent labeling change is expected to play a significant role in the proceedings, particularly in arguments concerning whether earlier disclosure was warranted based on available safety data.

The litigation has been consolidated into multidistrict litigation in federal court, where thousands of claims are currently pending.

Courts overseeing the Depo-Provera multidistrict litigation are preparing to evaluate key scientific evidence on whether the contraceptive injection is linked to intracranial meningioma brain tumors, with hearings expected to play a central role in determining which expert testimony will be presented at trial.

The litigation, consolidated in federal court in Florida, involves thousands of claims alleging that long-term use of Depo-Provera increases the risk of developing meningiomas.

The upcoming proceedings are expected to address whether the scientific studies supporting that link are reliable and admissible, a threshold issue that will shape how causation is presented to juries.

At issue is a growing body of research suggesting an elevated risk of brain tumors associated with prolonged exposure to medroxyprogesterone acetate, the hormone used in Depo-Provera.

Plaintiffs rely on this evidence to support claims that manufacturers failed to warn users, while defendants continue to dispute causation and maintain the product’s safety.

These hearings will directly impact the trajectory of the litigation by determining what expert opinions juries can consider, focusing on core issues of causation, product safety, and whether the alleged risks were sufficiently supported by scientific evidence.

A new Depo-Provera lawsuit is now pending in federal court in Georgia.

The plaintiff in this case, like countless other Depo-Provera lawsuits, claims Pfizer failed to warn U.S. patients about the drug’s supposed link to intracranial meningiomas, despite similar warnings appearing on labels in the European Union, U.K., and Canada.

According to the complaint, the plaintiff used Depo-Provera starting in the early 1990s and was later diagnosed with a meningioma that required surgery in March 2022, followed by ongoing treatment and serious complications.

The lawsuit alleges Pfizer was aware for years that Depo-Provera could cause or significantly contribute to meningioma development but failed to include that risk on the U.S. label.

The plaintiff also alleges Pfizer kept selling the 150 mg injection without including a warning or offering patients a lower-dose option.

Pfizer told Law360 that the claims are without merit and stated it will defend the case, while continuing to stand behind Depo-Provera’s safety and efficacy.

The Depo-Provera brain tumor MDL added 391 cases between March and April, increasing from 3,099 to 3,490.

The court continues to manage coordinated discovery and case organization, with no new JPML transfer activity reported during the month.

Our attorneys are actively accepting new clients for the Depo-Provera lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera lawsuit instantly.

A federal judge has reappointed approximately 70 attorneys to leadership positions in the ongoing multidistrict litigation involving Depo Provera and alleged links to meningioma brain tumors.

The court determined that current leadership has effectively managed the litigation to date and is best positioned to continue guiding the growing number of claims.

Leadership roles in multidistrict litigation are responsible for organizing discovery, coordinating legal strategy, and representing the interests of all plaintiffs involved in the consolidated proceedings.

The Depo Provera litigation centers on allegations that use of the injectable contraceptive is associated with an increased risk of meningioma, a type of brain tumor that can cause serious neurological complications.

Plaintiffs claim that manufacturers failed to adequately warn patients and healthcare providers about these potential risks.

The reappointment signals the court’s intent to maintain continuity as the litigation advances through critical pretrial phases, including evidence development and expert analysis.

The case remains in its early stages, and no determinations on liability or damages have been made.

The number of lawsuits filed over alleged Depo-Provera brain tumor risks continues to grow, with nearly 4,000 women now pursuing claims nationwide as the litigation moves closer to its first bellwether trial scheduled for December 2026.

All federal Depo-Provera lawsuits are currently consolidated in a multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Florida before Judge M. Casey Rodgers.

According to a recent joint status report, more than 3,300 cases are pending in the federal MDL alone, with hundreds of additional claims filed in state courts in New York and Delaware.

Judge Rodgers previously selected five representative cases to serve as bellwether trials, which are early test cases designed to help both sides evaluate how juries may respond to evidence and expert testimony that will likely be repeated throughout the litigation.

The first of those trials is currently scheduled to begin on December 7, 2026.

In the months leading up to trial, the parties are conducting expert discovery, including depositions of medical and scientific experts.

The court is also expected to hold hearings later this year on motions challenging whether certain expert testimony should be allowed before juries.

Meanwhile, Pfizer has indicated it may attempt to dismiss the claims using a federal preemption defense, arguing that federal drug labeling rules prevented the company from adding the warnings plaintiffs say were necessary.

The Depo-Provera litigation added 1,001 cases between February and March, increasing from 2,098 to 3,099.

The addition of more than one thousand Depo-Provera cases in the month is significant.

Within the litigation, the court continues to oversee coordinated discovery and initial case management within the federal multidistrict litigation.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly.

The Delaware Supreme Court declined to accept an interlocutory appeal challenging case-management orders in coordinated Depo-Provera product liability litigation, allowing the Superior Court’s framework to remain in place as the proceedings move forward.

The litigation currently involves more than 300 plaintiffs who allege that use of depot medroxyprogesterone acetate, marketed as Depo-Provera, caused them to develop intracranial meningiomas.

Pfizer and related entities are named as defendants, and similar claims are pending in a federal multidistrict litigation in Florida and in other state courts, with hundreds of additional filings expected in Delaware.

The challenged November 2025 orders were designed to streamline what is anticipated to become large-scale coordinated proceedings.

The Superior Court implemented an early focus on general causation, coordinated discovery efforts with the federal MDL and other state actions, appointed a third-party data administrator to manage document submissions through a centralized platform, and required plaintiffs to provide initial documentary proof of Depo-Provera use and a meningioma diagnosis.

Plaintiffs argued the trial court lacked authority to enter the orders and contended that the data administration requirement raised HIPAA-related concerns.

The Supreme Court held that the plaintiffs did not meet the strict standards required for immediate appellate review under Rule 42, emphasizing that interlocutory appeals are reserved for exceptional circumstances involving substantial issues of material importance.

The court agreed that the case-management directives function as procedural tools to manage complex litigation rather than decisions resolving the merits or substantive legal rights.

As a result, the coordinated structure will remain in effect while the underlying claims continue to proceed in Delaware alongside parallel actions nationwide.

A New York woman has filed a product liability lawsuit claiming that long-term use of Depo-Provera, a widely prescribed birth control shot, caused her to develop a meningioma brain tumor.

The complaint, filed February 16, 2026, names Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn LLC as defendants and argues the drug was sold without adequate warnings about serious neurological risks.

Depo-Provera contains high doses of the synthetic hormone medroxyprogesterone acetate and has been used by tens of millions of women in the U.S. since its FDA approval in the early 1990s.

Research published in 2024 indicated women who used Depo-Provera may be more than five times as likely to develop meningiomas compared to non-users.

Meningiomas, while often benign, can produce symptoms including memory loss, headaches, dizziness, vision disturbances, and seizures.

In response to these findings, federal regulators updated Depo-Provera’s labeling in late 2025 to include stronger warnings and guidance on monitoring for tumor development.

The recent lawsuit joins nearly 2,100 similar Depo-Provera lawsuits nationwide alleging that manufacturers failed to sufficiently inform patients and healthcare providers about the potential risks.

Plaintiffs seek compensation for medical expenses, lost income, and long-term impacts on quality of life.

Law firms in the United Kingdom are reviewing potential legal action on behalf of women who developed brain tumours after using a popular hormonal contraceptive injection, Depo-Provera. The emerging interest from plaintiffs’ counsel follows scientific and medical concerns that the drug may be associated with an increased risk of meningioma, a type of brain tumour, particularly among long-term users.

According to reports, several legal practices are assessing medical records, regulatory history, and epidemiological evidence as they consider whether to bring civil claims against the pharmaceutical manufacturer. These prospective claims may allege that the company failed to adequately warn patients and healthcare providers about a foreseeable risk of tumour development, or that it did not sufficiently investigate or disclose safety data before and after the product was marketed.

The review by UK law firms reflects similar litigation trends seen in other jurisdictions, where large cohorts of plaintiffs have pursued claims over allegedly harmful drug exposures. In many such cases, lawyers evaluate whether there is a plausible causal link between product use and serious health outcomes, whether warnings were timely and adequate, and whether regulatory agencies were misled or provided with incomplete information.

While no formal class action has yet been filed in the UK, the groundwork being laid could lead to widespread claims that test product liability principles under British tort law. Key issues in any future litigation may include whether the manufacturer knew or ought to have known about the risk, what safety studies were conducted, and how the drug was labeled and promoted to women and clinicians.

The potential emergence of these claims may also influence regulatory discussions about contraceptive safety monitoring and post-market surveillance, and could affect how courts in the UK approach allegations involving long-term pharmaceutical risks.

Pfizer is seeking dismissal of lawsuits alleging that its Depo Provera contraceptive injection caused users to develop intracranial meningioma tumors, arguing that the claims are barred by federal law.

Plaintiffs contend that long term use of Depo Provera increased their risk of developing brain tumors and that Pfizer failed to adequately warn patients and physicians of that risk.

In response, Pfizer has asserted a federal preemption defense, claiming that state law failure to warn claims cannot proceed because the U.S. Food and Drug Administration did not approve a label change adding a warning about meningioma risk.

Pfizer argues that it could not independently strengthen its warnings without FDA approval and therefore cannot be held liable under state law.

This type of defense is very common in large scale pharmaceutical and medical product litigation.

Drug manufacturers frequently invoke federal preemption in an effort to end cases early, particularly in mass tort actions involving FDA regulated products.

Courts often must closely examine whether the manufacturer truly lacked the ability to update warnings or whether relevant risk information was withheld or minimized during the regulatory process.

The resolution of Pfizer’s preemption arguments will be a key early issue in the Depo Provera litigation and may significantly impact whether the cases move forward into discovery and trial phases, following a path similar to other nationwide pharmaceutical injury lawsuits.

The Depo-Provera MDL added 346 cases between January and February, increasing from 1,752 to 2,098.

The filing surge reflects continued acceleration in new claims.

No significant JPML rulings or new docket developments were reported during the period.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

Lawyers involved in the federal Depo‑Provera multidistrict litigation have submitted a proposed schedule calling for the first bellwether trial to begin on December 7, 2026.

The case involves a Florida woman who alleges she developed a meningioma brain tumor after receiving Depo‑Provera birth control shots, experiencing vertigo, dizziness, and hearing loss that required brain surgery.

All federal Depo‑Provera lawsuits have been centralized in the U.S. District Court for the Northern District of Florida before Judge M. Casey Rodgers.

The litigation now includes more than 2,100 claims filed against Pfizer and generic manufacturers, all alleging the companies failed to adequately warn women about the risk of intracranial meningioma.

In late 2025, the FDA updated Depo‑Provera labeling to include a warning about brain tumor risks, recommending monitoring and discontinuation if meningioma develops.

The proposed schedule sets the close of fact discovery for August 14, 2026, summary judgment motions by October 2, and a final pretrial conference on November 20.

Additional bellwether trials are expected to begin in January 2027.

These early trials are designed to evaluate evidence and jury responses and may influence the handling of thousands of remaining cases.

Lawsuits alleging that the contraceptive injection Depo Provera increases the risk of meningioma brain tumors continues to expand in federal court, following recent regulatory and scientific developments.

The cases are consolidated in a multidistrict litigation pending in the U.S. District Court for the Northern District of Florida, where plaintiffs claim manufacturers failed to adequately warn about neurological risks associated with long term use.

The lawsuits focus on medroxyprogesterone acetate, the active ingredient in Depo Provera.

Plaintiffs allege that extended exposure to the drug contributed to the development of meningiomas, typically benign but potentially serious brain tumors that can cause symptoms such as headaches, memory loss, dizziness, vision problems, and seizures.

Many plaintiffs report being diagnosed only after years of unexplained neurological symptoms.

In December 2025, the U.S. Food and Drug Administration approved updated labeling for Depo Provera products, adding warnings about a potential increased risk of meningioma with prolonged use and recommending discontinuation if a tumor is diagnosed.

Plaintiffs argue that similar warnings should have been provided earlier, particularly given emerging research and regulatory actions in other countries.

The multidistrict litigation continues to grow as additional cases are filed nationwide.

Pretrial proceedings are focused on discovery, expert testimony, and legal challenges, including arguments by defendants that federal law preempts failure to warn claims.

Plaintiffs dispute that defense, asserting that manufacturers had sufficient evidence to support stronger warnings well before the FDA update.

The court is expected to select representative bellwether cases to proceed toward trial in late 2026 or 2027.

Outcomes in those cases may influence future settlement discussions or trial strategies across the litigation.

A federal judge has ordered attorneys serving in leadership roles in the Depo-Provera MDL to reapply if they intend to continue in those positions beyond March 2026.

The directive applies to lawyers appointed early in the federal litigation overseeing Depo-Provera lawsuits alleging a link between the birth control injection and meningioma brain tumors.

More than 1,752 Depo-Provera lawsuits are currently pending in the U.S. District Court for the Northern District of Florida before Judge M. Casey Rodgers.

The court centralized Depo-Provera lawsuits into a multidistrict litigation (MDL), a federal procedure that consolidates similar cases from across the country into one court for coordinated discovery and pretrial proceedings.

MDL consolidation is intended to reduce duplicative discovery, prevent inconsistent rulings, and streamline case management in complex litigations.

Depo-Provera lawsuits allege that manufacturers failed to adequately warn women and the medical community about the risk of meningioma associated with long-term use of the injectable contraceptive.

Judge Rodgers previously appointed 63 attorneys to leadership positions within the Depo-Provera MDL.

Leadership counsel perform work intended to benefit all plaintiffs, including coordinating discovery, engaging expert witnesses, and litigating common legal issues.

According to a pretrial order issued January 6, attorneys seeking reappointment must submit applications by February 13.

Each application is limited to two pages and must describe the work performed over the past year, including time commitments and resources devoted to the litigation.

Leadership appointments are scheduled to expire on March 16, 2026.

The court has selected five pilot cases, also known as bellwether trials. Bellwether trials are early test cases designed to evaluate how juries may respond to recurring evidence and testimony across the litigation.

Judge Rodgers has indicated that the first Depo-Provera bellwether trial should be trial-ready by mid-December 2026, with additional trials expected to begin in January 2027.

New filings in the Depo-Provera litigation continue to sharpen the focus on long-term use of the birth control shot and its alleged link to brain tumors, as more women report repeated surgeries and permanent neurological damage after years of injections without adequate warnings

According to a recently filed complaint, a woman who received Depo-Provera injections for more than a decade was diagnosed with intracranial meningioma and required multiple brain surgeries after the tumor repeatedly returned.

She alleges that despite early tumor diagnoses, she continued receiving the injections because neither she nor her doctors were warned that the drug could fuel tumor growth or recurrence.

The lawsuit points to scientific studies published in 2024 finding that women who received Depo-Provera faced a significantly increased risk of developing meningiomas compared to non-users.

Plaintiffs argue drugmakers knew or should have known about the hormonal link years earlier but failed to update warnings, allowing widespread use to continue without proper risk disclosure.

This case adds to a rapidly growing pool of more than 2,100 Depo-Provera brain tumor lawsuits now centralized in a federal MDL.

The litigation intensified after the FDA approved a label change in late 2025, adding a specific warning about intracranial meningioma and advising discontinuation of the drug if a tumor is diagnosed.

Why this matters: these claims highlight allegations that continued exposure after early tumor detection may worsen outcomes, increasing the need for repeat surgeries, lifelong monitoring, vision loss, and other permanent injuries.

As bellwether trials are scheduled to begin in late 2026, courts will closely examine what manufacturers knew about tumor risks and when they should have warned patients and physicians.

If early trial results favor plaintiffs, pressure could mount for broader settlements addressing years of alleged failure to warn millions of Depo-Provera users about serious brain tumor risks.

A woman from Tennessee has filed a new lawsuit claiming that Depo-Provera contributed to multiple brain tumors and surgeries, alleging long-term use of the birth control shot.

The plaintiff filed a case against Pfizer and related entities on December 6 in Delaware Superior Court, claiming she received Depo-Provera injections for years without any warning that the drug could increase the risk of brain tumors.

She says she was first diagnosed with a meningioma in 2008, had surgery that year, and continued receiving injections until 2017, with further tumor recurrences and surgeries in 2013 and 2014.

The complaint aligns with countless other lawsuits over Depo-Provera’s link to meningiomas.

In 2024, published studies showed that women who received the injections faced a significantly increased risk of developing brain tumors.

The FDA later approved updated label warnings advising monitoring for intracranial meningioma and discontinuation of the drug if one is diagnosed.

The plaintiff claims the manufacturers knew, or should have known, of the risk long before those warnings were added and failed to alert patients or doctors.

Her case will be transferred to the federal Depo-Provera MDL pending in the Northern District of Florida, where over 2,100 similar lawsuits are now consolidated.

Judge M. Casey Rodgers is managing coordinated discovery and a set of pilot cases designed to test key evidence and arguments, with the first trial currently scheduled for late 2026.

The FDA has approved a label change for the Depo-Provera birth control shot, adding a warning that use of the drug may increase the risk of meningioma, a tumor that forms in the lining of the brain.

The warning applies to both Depo-Provera CI and Depo-Subq Provera 104 and follows years of scientific literature examining a link between progestin exposure and meningioma development.

The FDA’s decision comes as Pfizer faces ongoing lawsuits from more than 1,000 women who allege the company failed to adequately warn patients and physicians about the brain tumor risk associated with long-term Depo-Provera use.

Court filings show Pfizer initially sought a label change in early 2024 after acknowledging awareness of the risk in 2023, but the FDA denied the request at that time.

After Pfizer amended and resubmitted its application in June 2025, the agency approved the warning, formally adding meningioma risk information to the product label.

The FDA action aligns the United States with regulators in Europe, Canada, and South Africa, which previously required meningioma warnings for high-dose medroxyprogesterone acetate products.

In the Depo-Provera lawsuit, plaintiffs argue the label change supports claims that women were not informed of known risks while the drug was widely prescribed, particularly among populations with high usage rates.

The litigation remains pending, but the FDA’s decision marks a significant development in how courts may evaluate failure-to-warn claims tied to Depo-Provera and brain tumor diagnoses.

The Depo-Provera MDL added 282 cases between December and January, bringing the total to 1,752.

The increase reflects accelerated plaintiff filings compared to prior months.

No major JPML activity or significant docket developments were reported during the period.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

As Depo-Provera Lawsuits against Pfizer, the birth control drug manufacturer, continue to be filed in federal court, the plaintiffs filed a motion to consolidate all litigations related to the injectable contraceptive before a single judge.

Pfizer agreed to this proposal but disagreed with the venue’s location and suggested a new venue to centralize the case.

More than 22 Depo-Provera Lawsuits have been filed in various U.S. District Courts nationwide.

Six of the 22 pending lawsuits are located in the Northern District of California, which the plaintiffs proposed is the most appropriate venue for centralizing all discovery and pretrial proceedings.

To ease the legal process, the plaintiffs also petitioned to combine these lawsuits into multidistrict litigation (MDL) to avoid repeating the same legal work in different courts.

In a response letter, Pfizer agreed to consolidate the lawsuits into one MDL.

Still, it has opposed the proposed venue and recommended that the cases be transferred to the Southern District of New York, where its corporate headquarters are located.

In their response letter, Pfizer said that the venue’s proximity to their headquarters allows for proximity to key witnesses and evidence, making it a more logical venue for the case.

The Judicial Panel on Multidistrict Litigation (JPML) will decide on the venue and combination of the Depo-Provera Lawsuits at a hearing on January 30th, 2025.

If approved, all current and future claims will be coordinated before a single judge for pretrial motions.

Individual Depo-Provera Lawsuits may go to trial if the cases are not settled.

Depo-Provera has been linked to a significantly increased risk of developing meningiomas, a type of brain tumor.

Recent studies suggest that women who used the drug face a five-fold greater risk compared to those who did not.

The majority of the lawsuits raise similar claims about Pfizer’s failure to warn women about the potential risks of meningiomas while using the drug, which is why the plaintiffs proposed an MDL.

Women who have suffered from meningiomas after using Depo-Provera are encouraged to explore their legal options as the litigation continues to evolve and grow.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The U.S. Food and Drug Administration approved a label change for Depo-Provera, adding a warning that the contraceptive shot may increase the risk of meningioma, a tumor that forms in the lining of the brain.

The warning applies to Depo-Provera CI and Depo-Subq Provera 104 and follows more than 1,000 lawsuits alleging that Pfizer failed to warn users about brain tumor risks associated with long-term exposure to medroxyprogesterone acetate.

Depo-Provera is administered every three months and contains a synthetic form of progesterone.

According to CDC data cited in court filings, approximately one in four sexually active women in the United States has used the shot, with higher usage rates among Black women, expanding the scope of potential exposure.

Although meningiomas are often classified as noncancerous, the tumors can cause serious neurological injury depending on size and location and may require brain surgery or radiation treatment.

Roughly 39,000 meningiomas are diagnosed annually in the United States.

Regulatory records show Pfizer told the FDA it became aware of the meningioma risk in 2023 and sought to add a warning in early 2024, a request the agency initially denied.

After Pfizer amended and resubmitted the application in June 2025, the FDA approved the label change.

The FDA action follows similar warnings issued in Europe, Canada, and South Africa involving high-dose progestins.

While Pfizer maintains Depo-Provera is safe when used as directed, plaintiffs’ attorneys argue the label change supports claims that women were not adequately warned for years as the Depo-Provera brain tumor litigation continues.

More and more women across the country are filing claims alleging that the contraceptive injection Depo-Provera can cause brain tumors known as meningiomas, with new lawsuits detailing neurological symptoms and accusing makers like Pfizer of failing to warn users about the risks.

Countless women across the United States are alleging that prolonged use of the progesterone-based birth control shot preceded the onset of symptoms such as vertigo, blurred vision, headaches, speech difficulties, and ultimately, diagnosis of meningioma.

The legal fight has intensified as more women file suits asserting that manufacturers overlooked, withheld, or failed to act on safety signals linking synthetic progestins to tumor development. 

Plaintiffs point to regulatory differences abroad, including updated warnings in Canada and Europe, noting that similar risk language was not included on U.S. labeling.

They argue that this discrepancy suggests companies were aware of emerging evidence yet did not adequately communicate it to American patients and clinicians.

Amid these claims,attorneys emphasize that conventional Depo-Provera warnings did not sufficiently alert users to the possibility of severe neurological harms, leaving women unaware of the potential danger.

Lawsuits allege negligent failure to warn, misrepresentation, and product defect, and they seek compensation for medical treatment costs, suffering, and long-term disability tied to brain tumor diagnoses and related neurological impairment.

The federal Depo-Provera MDL now includes over 2,100 filed cases, with more claims still moving through investigation.

Plaintiffs report that long-term use of Depo-Provera caused intracranial meningioma, a brain tumor that often needs surgery and ongoing neurological treatment.

Plaintiffs argue that Pfizer failed to warn users about the risk of meningioma linked to prolonged exposure to medroxyprogesterone acetate.

The litigation continues to focus on what the company knew about these risks and when the information should have been disclosed.

Judge Casey Rodgers, who oversees the MDL, has scheduled monthly status conferences throughout 2026 to monitor discovery and keep progress on expert challenges and early trial prep.

The court scheduled 12 conferences starting January 23, 2026, and running through December 18, 2026.

The Court also instructed both parties to select five pilot cases for early bellwether trials.

These cases will assess the strength of the scientific evidence and how juries react to the allegations.

Before any pilot trial can begin, plaintiffs must prove general causation—that Depo-Provera can cause meningioma.

Motions challenging general causation experts are due on March 22, 2026.

If those experts are permitted to testify, the pilot cases will proceed toward trial scheduling.

The Depo-Provera MDL added 245 cases between November and December, bringing the total to 1,470.

This continues a multi-month trend of growth as more plaintiffs join the litigation.

Claims generally allege that Pfizer failed to warn about long-term bone density loss and other serious side effects linked to the contraceptive injection.

More than 2,100 Depo-Provera lawsuits are now consolidated in the federal Depo-Provera Lawsuit MDL, with thousands of additional claims under investigation.

The lawsuits involve allegations that Depo-Provera birth control injections caused intracranial meningioma, a brain tumor that may require surgical removal and long-term neurological monitoring.

Plaintiffs allege that Pfizer failed to warn about the risk of meningioma associated with long-term exposure to medroxyprogesterone acetate, the synthetic progestin used in Depo-Provera.

The U.S. District Judge overseeing the Depo-Provera Lawsuit MDL, Casey Rodgers, has scheduled monthly status conferences throughout 2026 to manage discovery, expert challenges, and trial preparation.

The schedule includes 12 conferences from January 23, 2026, through December 18, 2026. 

These hearings will provide updates on discovery progress and ensure that both parties remain on track for upcoming deadlines involving general causation and bellwether preparation.

Judge Rodgers has ordered both sides to prepare five “pilot” Depo-Provera lawsuits for early bellwether trials. These trials are intended to evaluate how juries may respond to medical evidence and corporate conduct allegations.

Before any pilot trial proceeds, plaintiffs must establish general causation by showing that Depo-Provera can cause meningioma. Motions challenging general causation experts are due by March 22, 2026.

If the Court finds that general causation evidence is admissible, pilot trials will continue toward scheduling.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly.

More than 2,000 lawsuits have now been filed against Pfizer and other drugmakers over allegations that Depo-Provera birth control shots caused women to develop intracranial meningiomas, a type of brain tumor.

The surge in filings follows recent studies linking Depo-Provera to a 5.5x increased risk of brain tumors.

Plaintiffs claim the drug companies failed to warn users and the medical community for decades.

As of November 17, there are:

• 1,633 cases consolidated in the Northern District of Florida
• 322 plaintiffs across 13 cases in the Delaware state court
• 83 plaintiffs in 75 cases in the New York state court
• Additional cases filed in California (24), Illinois (5), Pennsylvania (2), and New Mexico (1)

The litigation is in early stages, with general causation discovery underway and a group of bellwether trials expected to be selected. Over 9,500 more claims remain under investigation.

Judge M. Casey Rodgers has extended key deadlines in the Depo-Provera brain tumor MDL by about six weeks, enabling the federal proceedings to sync with coordinated cases in New York and Delaware state courts.

Under the revised schedule, plaintiffs’ general-causation expert disclosures are due on December 1, 2025, defendants’ disclosures by January 9, 2026; and all expert depositions must be completed by February 20, 2026.

Any Rule 702 challenges to specialist testimony must be filed by March 22, 2026.

The adjustment comes after a conference on October 24 between federal and state court judges overseeing the litigation.

The extension provides both sides more time to review evidence on how long a product is used and the delay between Depo-Provera injections and tumor development.

Judge Rodgers formalized the updated timeline in Case Management Order No. 7, issued on October 30, 2025.

The next MDL status conference is scheduled for November 21, 2025.

The number of Depo-Provera claims increased slightly from 1,222 in October to 1,225 in November.

Plaintiffs allege the birth control injection caused osteoporosis and other bone-density complications after prolonged use.

The increase suggests ongoing interest from potential claimants and continued legal activity around long-term side effects.

The litigation remains in early phases with filings still coming into the docket.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly.

Three women have filed lawsuits in Florida federal court alleging that Pfizer’s contraceptive injection, Depo-Provera, caused them to develop brain tumors.

The cases join a rapidly growing multidistrict litigation that has expanded from 70 to over 1,300 suits since February.

The plaintiffs claim they used the drug for years before developing neurological symptoms such as vertigo, headaches, and vision problems that preceded tumor diagnoses.

Their complaints accuse Pfizer of failing to warn patients about the risk despite mounting scientific evidence connecting Depo-Provera and hormonal progestins to tumor development.

Pfizer maintains the claims are preempted by federal law, arguing that the FDA blocked its attempts to update warning labels and that Depo-Provera remains a safe, FDA-approved contraceptive used by millions worldwide.

Plaintiffs, however, argue the drug’s dosage is excessively high and that Pfizer prioritized profits over safety.

The outcome of these early cases could shape the broader litigation surrounding long-term Depo-Provera use and women’s health risks.

The Depo-Provera multidistrict litigation (MDL No. 3140) continues to progress as parties coordinate with parallel cases in Delaware and New York state courts.

The MDL currently includes 1,346 total cases, with 1,332 complaints deemed complete and 509 plaintiffs submitting full proof of use and meningioma diagnosis documentation.

The parties are aligning their general causation schedules across jurisdictions. If adopted by all courts, the unified deadlines will be:

• Plaintiffs’ general causation expert disclosures: December 1, 2025
• Defendants’ disclosures: January 9, 2026
• Expert depositions completed: February 20, 2026
• Rule 702 motions filed: March 22, 2026
• Oppositions to Rule 702 motions: April 21, 2026
• Optional replies (if permitted): April 28, 2026

This phase is crucial for determining whether plaintiffs can prove that Depo-Provera’s active ingredient, medroxyprogesterone acetate, can cause meningioma brain tumors.

State Court Coordination

• New York: 78 plaintiffs are now consolidated under Judge Sabrina Kraus. BrownGreer is assisting with threshold reviews.
• Delaware: 332 plaintiffs are involved, though a procedural dispute with the Keller Postman firm remains over threshold proof orders.
• California, Illinois, Pennsylvania, Connecticut, and New Mexico: Cases are active and at varying stages of motion practice and scheduling

Product Use and Injury Documentation

Under PTOs 17, 22, and 22A, plaintiffs continue submitting evidence of Depo-Provera use and meningioma diagnosis through MDL Centrality.

The court-appointed vendor BrownGreer is managing document intake and validating case completeness.

Thousands of women have filed claims alleging that the injectable contraceptive Depo-Provera caused them to develop meningiomas, a form of brain tumor.

The lawsuits target Pfizer and other manufacturers, alleging they failed to warn users about known risks tied to long-term use of the hormone-based shot.

A 2024 British Medical Journal study found women using certain high-dose progestogen drugs faced up to a sixfold higher risk of developing these tumors.

While regulators in Europe and Canada have added warnings to Depo-Provera labels, U.S. labels have not yet changed, fueling allegations of negligence and misrepresentation.

Plaintiffs argue the companies prioritized profits over safety and withheld evidence from the public.

The Depo-Provera lawsuit saw a notable rise in activity between September and October, increasing from 806 cases to 1,222.

This 50%+ increase signals growing awareness of alleged long-term effects linked to the injectable birth control, particularly concerning bone density loss and other serious health complications.

As more claimants come forward, this trend may continue if public exposure and legal advertising persist.

The litigation is still in its early stages, but the sharp month-over-month growth points to heightened momentum.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

The multidistrict litigation over Pfizer’s contraceptive Depo-Provera now includes more than 1,300 plaintiffs, up from just over 70 in February, as a critical September 29 hearing on federal preemption approaches in the Northern District of Florida.

Plaintiffs allege the drug increases the risk of meningiomas, slow-growing brain tumors, and claim Pfizer failed to warn consumers despite growing scientific evidence, including a recent JAMA Neurology study linking long-term use to a twofold higher risk.

Plaintiffs in the Depo Provera brain tumor lawsuit filed a firm opposition to Pfizer’s attempt to dismiss the case based on federal preemption.

The brief argues that Pfizer concealed vital information about meningioma risks from the FDA, minimized epidemiological studies, and disregarded decades of mechanistic evidence.

According to the plaintiffs, Pfizer even disclosed more to foreign regulators than to U.S. officials.

The filing also highlights that the FDA has never rejected a sufficient warning.

Plaintiffs cite a 2024 Complete Response Letter as evidence that stronger warnings were always possible and argue that Pfizer’s subsequent withdrawal of low-dose Depo Provera supports this point.

They argue that a broad reference to meningioma does not fulfill Pfizer’s duty to warn about risks specifically linked to high-dose injectable MPA.

Finally, the opposition claims that Pfizer could have marketed safer options, such as the SubQ formulation, and nothing in federal law prevented it.

Plaintiffs contend this undermines Pfizer’s argument of “impossibility,” which is the critical standard for preemption.

If accepted, the argument preserves the litigation and prevents Pfizer from avoiding liability through preemption.

According to the August 25, 2025 Case Management Order (CMO), the next Case Management Conference is scheduled for Monday, September 29, 2025, at 9:00 a.m. Central Time in the U.S. District Court for the Northern District of Florida.

Oral arguments on preemption will follow the conference.

These proceedings are expected to shape the future of the litigation by addressing whether federal law preempts plaintiffs’ state law failure-to-warn claims: an issue that could influence the outcome of thousands of cases.

Visit this page for further information and news on the Depo Provera Lawsuit as these integral meetings and conferences are completed.

Thousands of women across the U.S. are filing lawsuits alleging that Depo-Provera birth control injections caused them to develop intracranial meningioma brain tumors.

As of now, over 10,000 women are pursuing or preparing to file Depo-Provera lawsuits, claiming the manufacturer failed to warn about the 5.5x increased risk of developing meningiomas linked to the hormone medroxyprogesterone acetate, the active ingredient in the long-acting birth control shot.

Many women diagnosed with meningiomas years after receiving Depo-Provera are only now learning about the potential connection.

Others are reporting neurological symptoms such as headaches, vision problems, and dizziness, which they now fear could be signs of an undiagnosed brain tumor.

Recent lawsuits include both individual injury claims and class action complaints demanding medical monitoring for women who used the injection and are concerned about long-term tumor risks.

Depo-Provera has been in use for decades and was widely marketed as a safe, convenient contraceptive option.

Plaintiffs allege that the manufacturer failed to adequately disclose the serious risks associated with the drug and demand accountability for failing to provide sufficient warnings.

Women sharing their experiences have reported lifelong fears and uncertainty about their health due to these alleged risks.

A new JAMA Neurology study published online September 2, 2025, highlights a biologically plausible connection between female sex hormones and the development and growth of meningiomas—the most common primary brain tumors, which are predominantly benign and occur at a rate of 6 to 8 new cases per 100,000 people annually.

The study highlights that meningiomas have a well-documented sex predilection, with incidence rising after puberty, and more than 60% of these tumors express progesterone receptors.

Moreover, tumor size appears to increase during periods of elevated estradiol and progesterone levels, such as during childbearing years and pregnancy JAMA Network.

These scientific findings sit at the heart of escalating litigation.

In February 2025, litigation over Depo-Provera (DMPA) was centralized in MDL No. 3140 in the Northern District of Florida, where more than 500 cases are now pending.

Plaintiffs, many of whom developed meningiomas and subsequently suffered significant neurological complications (like seizures, vision loss, or cognitive impairment) allege that Pfizer failed to adequately warn users, despite long-standing scientific signals.

Pfizer has moved to dismiss failure-to-warn claims on the grounds of federal preemption, noting that in late 2023, the FDA declined to approve a labeling update regarding meningioma risk.

The company argues this regulatory refusal precludes state-law claims alleging failure to warn Reuters.

Plaintiff attorneys counter that Pfizer had been aware (since at least the 1980s) of growing evidence linking DMPA to meningioma risk and nonetheless failed to protect patients.

To test these competing claims, the court has designated five “pilot” cases to proceed first.

The initial rulings on Pfizer’s preemption argument and the validity of the scientific evidence will likely shape the direction of the broader litigation, influencing both settlement dynamics and whether remaining cases move forward

The number of Depo-Provera lawsuits awaiting consolidation continues to grow.

In September, 806 cases were centralized in the Depo Provera MDL, compared to 550 in August.

This increase of more than 250 cases in one month highlights the rapid pace at which new claims are being filed.

The pending litigation involves allegations that the birth control injection Depo-Provera caused serious health complications, including bone density loss and breast cancer.

Plaintiffs across the country are seeking consolidation through the Judicial Panel on Multidistrict Litigation (JPML).

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly.

Nearly 1,000 Depo-Provera meningioma lawsuits are now pending nationwide, while more than 9,500 additional claims are still under investigation. 

The lawsuits allege that long-term use of Depo-Provera, a hormonal contraceptive injection, increased the risk of meningioma, a brain tumor that can lead to neurological impairment, headaches, and vision loss.

Earlier this year, the Judicial Panel on Multidistrict Litigation (JPML) consolidated Depo-Provera lawsuits into multidistrict litigation (MDL) before U.S. District Judge M. Casey Rodgers in the Northern District of Florida. Multidistrict litigation streamlines pretrial proceedings by centralizing federal claims with common issues, allowing coordinated discovery and early test trials.

Pfizer, the manufacturer of Depo-Provera, is expected to file a motion for summary judgment this month, arguing that federal law preempts the claims.

If the litigation proceeds past the preemption challenge, five bellwether cases will be prepared for early jury trials. 

Bellwether trials provide insight into how juries may respond to evidence and testimony, and the results often shape broader settlement negotiations.

Depo-Provera contains medroxyprogesterone acetate, a synthetic progestin administered every three months as birth control.

The lawsuits reference recent research indicating that women who used Depo-Provera for more than one year faced a more than fivefold increased risk of developing meningioma.

Plaintiffs allege that Pfizer failed to adequately warn about these risks and prioritized sales over patient safety.

An Ohio woman has filed a lawsuit against Pfizer and other manufacturers of Depo-Provera, alleging the birth control shot caused her to develop a debilitating brain tumor requiring lifelong medical monitoring.

The plaintiff began using Depo-Provera in 1994 and received the injections for 10 years.

She was diagnosed with an intracranial meningioma in 2023 after experiencing symptoms such as seizures, balance problems, and persistent headaches.

The lawsuit claims that the manufacturers failed to adequately warn about the risk of brain tumors linked to depot medroxyprogesterone acetate (DMPA), the active ingredient in Depo-Provera.

Shepherd underwent surgery to remove the tumor, but now requires routine MRIs and CT scans to monitor for recurrence and faces long-term psychological distress due to the risk of future neurological damage.

Filed in the Northern District of Florida, Shepherd’s case is part of the growing Depo-Provera brain tumor litigation now consolidated under U.S. District Judge M. Casey Rodgers.

Early “pilot” trials are being prepared to test the strength of the claims before juries.

Plaintiffs argue that the drug’s manufacturers ignored data linking DMPA use to intracranial meningiomas and failed to update warnings despite mounting evidence.

A new Depo-Provera lawsuit filed by a Louisiana woman alleges she developed an intracranial meningioma after receiving Depo-Provera injections from 2001 to 2012.

Her symptoms escalated to include full-body numbness on the left side, culminating in invasive brain surgery in 2019

The Plaintiffs case joins over 550 others now centralized in a multidistrict litigation (MDL) before Judge M. Casey Rodgers in the Northern District of Florida.

The lawsuits accuse Pfizer and its affiliated companies of failing to warn patients and doctors about the risks of intracranial meningiomas tied to prolonged exposure to medroxyprogesterone.

Medroxprogesterone is the active ingredient found in the Depo-Provera shot.

Scientific studies have indicated that synthetic progestins like those in Depo-Provera may contribute to tumor growth.

Plaintiffs argue that these dangers were known or should have been known long before recent research brought them to light.

Bellwether trials are now being prepared to assess jury reactions to the core evidence and expert testimony.

These early trials will help shape the future of potential settlements or continued litigation for thousands of women affected.

The Depo-Provera MDL grew by 115 cases between July and August, bringing the total to 550.

Plaintiffs continue to allege that Pfizer’s injectable contraceptive caused them to suffer serious bone density loss.

The increase reflects steady plaintiff-side activity as more individuals come forward with long-term health concerns tied to the product.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

The federal judge overseeing the growing number of Depo-Provera brain tumor lawsuits is pressuring plaintiffs’ lawyers to disclose how many cases remain unfiled.

Judge M. Casey Rodgers, who presides over the MDL in the Northern District of Florida, raised concerns that attorneys are delaying the filing of claims until the court rules on key preemption defenses later this year.

As of now, more than 550 lawsuits have been filed by women who developed meningiomas after receiving Depo-Provera, a long-acting birth control injection manufactured by Pfizer and generic drugmakers.

However, plaintiffs have indicated that hundreds (or potentially thousands) more cases are likely to be filed.

The lawsuits claim that Depo-Provera increases the risk of intracranial meningiomas, citing recent studies showing a five-fold increased risk in certain users.

Plaintiffs argue that the drug manufacturers failed to warn women and healthcare providers of this danger.

Judge Rodgers warned that delaying the filing of cases until after a decision on Pfizer’s preemption defense (which argues that federal law barred it from changing the warning label) is disruptive to the litigation process.

She made clear that leadership roles in the MDL could be revoked if firms wait to file en masse after the ruling.

The deadline to certify the number of unfiled claims is July 31, and oral arguments on preemption are scheduled for September 29.

If the claims survive, five bellwether trials will move forward, offering key insights into jury response and influencing possible settlement talks.

A Nebraska woman has filed a product liability lawsuit against Pfizer Inc., alleging that her long-term use of the injectable contraceptive Depo-Provera caused her to develop multiple meningiomas, requiring invasive brain surgeries.

The lawsuit, filed on July 16, 2025, in the U.S. District Court for the Northern District of Florida, joins a growing multidistrict litigation (MDL No. 3140) involving over 500 similar claims.

The plaintiff, Amy Samsel, used Depo-Provera for more than 21 years before being diagnosed with two brain tumors in 2023.

According to the complaint, the tumors led to neurological symptoms including dizziness, vision problems, and papilledema. She underwent two craniotomies to remove the tumors.

Samsel alleges that Pfizer and other defendants failed to warn about the known risk of intracranial meningiomas associated with long-term use of Depo-Provera.

The suit cites scientific research dating back to the 1980s, including a 2024 French study linking prolonged progestin use with a 5.6-fold increased risk of meningioma.

While European and Canadian regulators have added meningioma warnings to Depo-Provera labeling, similar disclosures have not been implemented in the U.S.

Claims in the lawsuit include failure to warn, design defect, negligence, misrepresentation, and breach of warranty.

The case is part of coordinated pretrial proceedings overseen by Judge M. Casey Rodgers, who has scheduled a series of bellwether trials to begin in the coming year.

The outcome of early trial cases may influence the direction of future settlements or rulings in the MDL.

More than 550 product liability lawsuits have been filed against Pfizer over allegations that its contraceptive injection, Depo-Provera, caused users to develop meningioma brain tumors.

Depo-Provera Lawsuits have been consolidated in federal multidistrict litigation (MDL No. 3140) in the U.S. District Court for the Northern District of Florida under Judge M. Casey Rodgers.

Countless plaintiffs allege they developed serious brain tumors after receiving Depo-Provera injections over extended periods.

Discovery is currently underway, and early bellwether trial selections are expected in late 2025 or early 2026.

Pfizer is expected to challenge the claims through preemption defenses, asserting that federal regulatory approval of Depo-Provera bars state-level failure-to-warn claims. Briefing on these motions is anticipated later this year.

Depo-Provera packaging in the U.S. does not currently include a warning about meningioma risks.

In contrast, regulators in Europe and Canada require such warnings.

Plaintiffs in the MDL generally allege that Pfizer knew or should have known about the risk and failed to adequately inform users and the medical community.

The lawsuits seek compensation for medical expenses, lost wages, and long-term disability associated with brain tumor treatment.

TorHoerman Law is currently reviewing potential claims involving individuals who developed meningioma after receiving Depo-Provera injections.

On July 9, 2025, U.S. District Judge M. Casey Rodgers issued a pretrial order requiring all plaintiffs involved in the Depo-Provera multidistrict litigation (MDL) to disclose details of any pre-settlement funding arrangements.

The order mandates attorneys to submit documentation identifying the funding company, loan amount, interest rate, fees, and repayment terms.

The court expressed concern that some plaintiffs may have entered into high-interest funding agreements that could influence their settlement decisions.

Judge Rodgers emphasized the need to protect plaintiffs from predatory lending practices that may erode their financial recovery and interfere with the resolution of the litigation.

The disclosure order follows a broader judicial trend of increasing transparency around third-party litigation financing, particularly in mass tort cases where plaintiffs may face financial hardship while awaiting trial or settlement.

The Depo-Provera MDL consolidates claims alleging that the injectable birth control caused irreversible bone density loss and other long-term health effects.

Pretrial proceedings continue as parties engage in coordinated discovery and settlement discussions.

Pfizer is currently facing a growing wave of litigation in both the U.S. and U.K. from hundreds of women who claim that long-term use of Depo-Provera caused them to develop meningiomas—noncancerous but potentially dangerous brain tumors.

The lawsuits were filed following a 2024 British Medical Journal study that linked progestogens, the hormone used in Depo-Provera, to a significantly increased risk of meningiomas.

The study found that women using the injection for over a year had a 5.6 times greater likelihood of developing the tumors.

A separate 2024 study published by the National Library of Medicine supported these findings.

Despite these emerging concerns, Depo-Provera’s official U.S. label still does not mention meningioma risks as of mid-2025.

Plaintiffs allege Pfizer was aware of these dangers but failed to warn consumers or update safety information in the U.S., even though similar warnings were issued in other countries.

Depo-Provera is approved to prevent pregnancy for three months per injection and is not recommended for use beyond two years.

Plaintiffs argue that Pfizer failed to communicate safer alternatives or adequately update risk disclosures, potentially exposing millions of women to long-term harm.

The Depo-Provera MDL rose to 435 cases by July 1st, up from 348 in June.

This is the largest monthly increase reported since tracking began.

Plaintiffs allege that the birth control injection caused bone density loss and other long-term health complications.

The litigation is still in early procedural stages, with coordination focused on consolidating claims and case management.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly.

On June 11, U.S. District Judge M. Casey Rodgers, who is presiding over the federal multidistrict litigation (MDL) regarding Depo-Provera birth control shots, issued a case management order.

This order suggests that the authorized generic manufacturers Greenstone, Viatris, and Prasco will likely be excluded from the litigation soon.

During a case management conference on May 30, plaintiffs’ attorneys suggested that these companies are expected to be released, awaiting further assessment of their role related to the drug.

The MDL now encompasses over 400 Depo-Provera Lawsuits, centering on claims that these birth control injections contributed to the development of meningioma brain tumors, with Pfizer and other brand-name manufacturers purportedly failing to disclose this risk.

Since March 2025, over 300 lawsuits have been consolidated.

Discovery is ongoing, as the deadlines for producing documents related to preemption and general causation have passed since May 11.

Judge Rodgers stated that bellwether trials are slated to begin in late 2026 or early 2027 to assess key arguments and support possible settlements.

On September 29, 2025, U.S. District Judge M. Casey Rodgers will hear oral arguments on Pfizer’s motion to dismiss over 400 lawsuits filed in the Depo-Provera brain tumor multidistrict litigation.

The motion centers on federal preemption, a legal doctrine that could block the cases from proceeding to discovery.

Pfizer argues that it cannot be sued under state failure-to-warn laws because the U.S. Food and Drug Administration previously rejected a proposed warning about brain tumor risks for Depo-Provera.

The company contends that federal law preempts any state law claims requiring a warning the FDA declined to approve.

Plaintiffs argue that Pfizer has not met the high burden required to invoke preemption and maintain that the FDA’s denial did not amount to a categorical prohibition on additional warnings.

They assert that drug manufacturers can still be held liable under state law when new evidence of risk emerges. Plaintiffs cite recent studies linking Depo-Provera to increased risks of brain tumors as justification for their claims.

The court’s decision could determine whether the federal litigation moves forward into discovery or is dismissed at the threshold. A ruling is expected in October.

Pfizer has requested that the Philadelphia Court of Common Pleas establish a mass tort program for lawsuits concerning Depo-Provera brain tumors.

Although only two lawsuits have been filed in Philadelphia so far, one involves over 100 plaintiffs.

Nearly all the plaintiffs had their claims severed and dismissed without prejudice on May 30, allowing them to refile individually.

Pfizer expects a surge in new filings and argues that centralizing the cases will streamline the litigation process.

Attorneys anticipate that the court’s decision on whether to approve the mass tort program could greatly affect how the Pennsylvania docket proceeds.

TorHoerman Law associate attorney Alexis Robinson has provided an update on the progress of the Depo-Provera Lawsuits.

Judge Casey Rogers has been assigned to oversee the litigation and has set regular status conferences through 2025 to keep the case on track.

She recently issued an order to show cause against the manufacturers, Greenstone and Biatric, for missing court-imposed deadlines.

In addition, she selected five early cases to proceed as bellwether trials, a significant step that can help determine how the larger pool of cases may be resolved.

Judge Rogers has also implemented a streamlined process for obtaining medical records and issuing subpoenas to medical providers and pharmacies.

Her prior experience managing large-scale mass torts is expected to support an efficient and organized path forward in the Depo-Provera Lawsuit proceedings.

Her active management may help accelerate progress toward resolution.

The court’s increasing activity makes it important for potential claimants to act quickly, as the time to join the litigation may be limited.

Individuals who believe they may qualify should start the process by completing the online chat feature evaluation on our website.

Current clients should ensure they complete the onboarding process in full to avoid missing deadlines that could impact their claims.

As with all complex litigation, timelines and procedures may shift as the case evolves.

The information provided here reflects current expectations and should be viewed as a general update rather than a guarantee of outcome or timing.

The Depo-Provera MDL grew by an additional 59 new cases between May and June, bringing the total to 348.

Lawyers are reviewing medical histories and expert reports as preliminary discovery efforts begin to shape the core claims in the litigation.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

As litigation over alleged brain tumor risks tied to Depo-Provera continues to grow, attention is turning to a lower-dose alternative that some experts say may have posed fewer risks to long-term users.

Depo Sub-Q Provera 104, a formulation developed by Pfizer, delivers 104 mg of medroxyprogesterone acetate via subcutaneous injection.

That’s significantly less than the 150 mg dose delivered intramuscularly in the traditional Depo-Provera shot.

Medical experts suggest the lower dose could have substantially reduced the risk of meningioma, which are non-cancerous brain tumors linked to long-term use of synthetic hormones.

They believe this is because a lower dose would lead to less hormone buildup in the body over time.

Despite this potential safety benefit, Pfizer made limited efforts to transition patients to the lower-dose version, according to attorneys representing plaintiffs in the Depo-Provera multidistrict litigation (MDL).

Lawyers argue the decision to continue promoting the higher-dose product was driven more by market considerations than medical ones.

A new peer-reviewed study published in February 2025 has added significant weight to the growing body of evidence linking Depo-Provera to brain tumors.

Researchers from the University of British Columbia conducted a large-scale nested case-control study comparing users of Depo-Provera to users of a common oral contraceptive (ethinylestradiol-levonorgestrel).

Their analysis, based on U.S. insurance claims data, found that women who used Depo-Provera for more than one year were 3.5 times more likely to develop meningioma than those on oral contraceptives.

The researchers used rigorous methods to account for disease latency and other confounding factors, addressing concerns raised by earlier studies that lacked active comparators or control for the timing of tumor development.

Notably, the risk remained elevated even after longer use, with adjusted incidence rate ratios of 2.95, 3.17, and 3.50 for two, three, and four years of use, respectively.

The study underscores a possible biological mechanism for the risk, as meningiomas frequently overexpress progesterone receptors—the same receptors targeted by Depo-Provera to prevent pregnancy.

Although the European Medicines Agency has recommended adding meningioma warnings to Depo-Provera’s label, the U.S. FDA has not yet followed suit.

Plaintiffs in the Depo-Provera multidistrict litigation (MDL) have cited emerging studies like this one to argue that Pfizer failed to adequately warn women about long-term tumor risks.

With over a million prescriptions filled annually, the findings are expected to play a key role in both ongoing discovery and potential bellwether trials in the Depo-Provera brain tumor MDL.

159 cases have been added to the Depo-Provera MDL in the past month, the largest influx of cases since the MDL was established.

As more individuals become aware of the links between Depo-Provera and brain tumors, the number of lawsuits continues to increase.

The federal lawsuit for Depo-Provera brain tumors is progressing quickly, with the MDL judge ironing out which defendants will remain named in the lawsuit and which are dismissed.

The MDL judge is implementing strict deadlines for defendants and has ruled that early depositions will not be necessary at this stage of the litigation.

The Depo-Provera Lawsuit is ongoing. 

The Depo-Provera brain tumor multidistrict litigation (MDL) is progressing, with U.S. District Judge M. Casey Rodgers issuing decisive rulings aimed at maintaining efficiency and transparency.

In recent weeks, the judge accepted affidavits from generic drug manufacturers Greenstone, Viatris, and Prasco, addressing their alleged involvement with the birth control shot linked to brain tumors such as meningiomas.

Prasco submitted its affidavit on time, while Greenstone and Viatris initially failed to comply—prompting an Order to Show Cause.

However, the court has since confirmed receipt of all affidavits and ruled that early depositions will not be necessary at this stage.

This streamlines the discovery process without waiving plaintiffs’ rights to challenge the generics’ role later in litigation.

Plaintiffs’ attorneys are close to reaching a stipulation that may result in Prasco’s dismissal from the MDL.

Greenstone and Viatris, however, remain active defendants and are expected to fully comply with upcoming discovery obligations regarding product distribution and liability.

Judge Rodgers’ active case management has ensured steady progress in a rapidly growing MDL, which now includes thousands of women alleging they developed brain tumors after receiving Depo-Provera injections.

The court’s insistence on strict deadlines sends a strong message that delays and noncompliance will not be tolerated.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The federal judge overseeing all Depo-Provera brain tumor lawsuits has scheduled monthly case management conferences through 2025, aimed at keeping the litigation on track for early bellwether trials.

These lawsuits, centralized in a multidistrict litigation (MDL) before U.S. District Judge M. Casey Rodgers in the Northern District of Florida, involve claims that Pfizer and other manufacturers failed to warn about the risk of meningioma brain tumors linked to long-term use of the birth control injection.

As of now, at least 130 cases have been filed, though that number is expected to grow significantly.

In a proactive move, Judge Rodgers independently selected five pilot cases for early trials and is pushing both sides to make consistent progress.

The next status conference is scheduled for May 30.

While early trials may not begin until late 2026 or early 2027, their outcomes are expected to shape future settlement negotiations and influence the direction of thousands of similar claims.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

U.S. District Judge M. Casey Rodgers is holding parties accountable in the Depo-Provera brain tumor MDL, recently issuing an order to Show Cause after generic manufacturers Greenstone and Viatris missed a court deadline.

The defendants were given fourteen days under Case Management order No. 2 to submit the documentation to file a Notice of Compliance.

While Prasco met the deadline, Greenstone and Viatris did not.

This type of court order, which demands an explanation for failure to follow judicial instructions, can carry serious consequences.

Although both later submitted required affidavits confirming non-involvement with the drug, the judge warned that future delays will not be tolerated.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A recent court order in the Depo-Provera multidistrict litigation (MDL) has established a formal procedure for plaintiffs to verify their medication use.

According to this ruling, plaintiffs must submit a “Plaintiff Proof of Use/Injury Questionnaire” within 120 days of March 14, 2025, or within 120 days of filing for newly added cases.

To aid in this process, the court has approved a method for obtaining third-party records to confirm whether individuals received Depo-Provera or its generic alternative, DMPA.

Since many plaintiffs may have received the injection years ago, accessing conventional medical records can be challenging.

The court order requires that third-party organizations, including pharmacies, healthcare providers, insurers, and military medical institutions, produce documents that may assist in verifying usage.

This documentation could include purchase histories, shipping logs, or insurance payment data that indicate a facility’s administration of Depo-Provera or a similar medication.

To simplify the retrieval of these records, the court has authorized plaintiffs to use a standardized HIPAA and HITECH-compliant release form and a medical provider identification form.

If a provider does not voluntarily comply with a request, plaintiffs’ legal teams can issue subpoenas without encountering additional procedural barriers.

Additionally, the order mandates that third-party entities comply with these subpoenas or requests without imposing unnecessary administrative burdens.

Restrictions such as proprietary forms, original signatures, or excessive processing fees that might obstruct access to records are prohibited.

This court directive represents a significant advancement in enabling plaintiffs to obtain crucial documentation to support their cases.

By offering a structured and enforceable method, it seeks to reduce challenges related to incomplete or inaccessible medical records, thus enhancing efficiency in the litigation process.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A recent court order in the Depo-Provera multidistrict litigation (MDL) has established a formal procedure for plaintiffs to verify their medication use.

According to this ruling, plaintiffs must submit a “Plaintiff Proof of Use/Injury Questionnaire” within 120 days of March 14, 2025, or within 120 days of filing for newly added cases.

To aid in this process, the court has approved a method for obtaining third-party records to confirm whether individuals received Depo-Provera or its generic alternative, DMPA.

Since many plaintiffs may have received the injection years ago, accessing conventional medical records can be challenging.

The court order requires that third-party organizations, including pharmacies, healthcare providers, insurers, and military medical institutions, produce documents that may assist in verifying usage.

This documentation could include purchase histories, shipping logs, or insurance payment data that indicate a facility’s administration of Depo-Provera or a similar medication.

To simplify the retrieval of these records, the court has authorized plaintiffs to use a standardized HIPAA and HITECH-compliant release form and a medical provider identification form.

If a provider does not voluntarily comply with a request, plaintiffs’ legal teams can issue subpoenas without encountering additional procedural barriers.

Additionally, the order mandates that third-party entities comply with these subpoenas or requests without imposing unnecessary administrative burdens.

Restrictions such as proprietary forms, original signatures, or excessive processing fees that might obstruct access to records are prohibited.

This court directive represents a significant advancement in enabling plaintiffs to obtain crucial documentation to support their cases.

By offering a structured and enforceable method, it seeks to reduce challenges related to incomplete or inaccessible medical records, thus enhancing efficiency in the litigation process.

Additionally, the Depo-Provera Lawsuit experienced a significant increase in new filings between March and April 2025.

Between February and March, the litigation saw 78 new cases filed.

By April 1st, the number of Depo-Provera Lawsuits pending surged to 130, an increase of 52 new cases.

This notable rise in filings reflects growing attention to the potential risks associated with Depo-Provera, particularly in relation to claims of brain tumor risk linked to its use.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Lawsuit is ongoing. 

The U.S. District Judge overseeing Depo-Provera brain tumor lawsuits has authorized direct filing in the multidistrict litigation (MDL), streamlining the process as more women file claims against the birth control shot’s manufacturer.

Judge M. Casey Rodgers, presiding in the Northern District of Florida, issued a case management order allowing plaintiffs to file directly in the MDL, avoiding delays from transferring cases between courts.

The litigation centers on allegations that Depo-Provera increases the risk of meningioma, a type of benign brain tumor, and that manufacturers failed to warn women and doctors.

Unlike typical mass tort cases, the MDL will not require a master complaint, short-form complaints, or a Science Day, as the court deemed them unnecessary.

Judge Rodgers has also appointed 63 attorneys to leadership roles, including those overseeing discovery, expert testimony, and trial preparation.

The litigation is expected to grow rapidly, with five pilot cases selected for early bellwether trials.

The MDL webpage is now live for case updates, and the next status conference date is pending.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera multidistrict litigation (MDL) is progressing under Judge Rodgers, with both sides finalizing a structured case management plan.

Plaintiffs can now file cases directly into the MDL, expediting the process by which individuals can file Depo-Provera Lawsuits.

A pilot case schedule is in place, setting deadlines for amended complaints, discovery, expert disclosures, and dispositive motions.

A central dispute remains: whether expert testimony is necessary on preemption.

Plaintiffs argue it is, while Defendants seek early dismissal based on legal grounds.

Key agreements include confidentiality protections, proof of Depo-Provera use and injury, and Pfizer’s document production requirements.

Plaintiffs secured 35 deposition days for Pfizer witnesses, plus additional time for other Defendants, with remote and video depositions permitted.

Generic distributors Greenstone and Prasco may be dismissed in cases where Plaintiffs didn’t use their products.

Special Master David Herndon and CPA Randall Sansom will oversee case management and attorney compensation.

Both sides agreed that a Science Day is unnecessary for now, keeping medical monitoring class actions on hold.

Discovery is now underway, and more developments are expected in the coming months.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A new case report warns that Depo-Provera birth control shots may increase the risk of severe blood clots, following a 21-year-old woman’s multiple pulmonary embolisms shortly after receiving the injection.

Doctors at Cape Fear Valley Medical Center documented the case in the journal Cureus, describing how the patient developed phlegmasia cerulea dolens (PCD), a rare and life-threatening form of deep vein thrombosis (DVT).

She required extensive medical intervention, including thrombectomy and anticoagulation therapy.

This follows a recent JAMA study linking Depo-Provera to the highest risk of serious blood clots among hormonal contraceptives.

Meanwhile, Depo-Provera Lawsuits over brain tumors are rapidly increasing, with about 70 cases consolidated in multidistrict litigation (MDL) in Florida.

More claims are expected as women diagnosed with intracranial meningiomas connect their condition to the long-term use of the contraceptive.

The court is preparing for bellwether trials to help determine how juries will respond to evidence.

If settlements are not reached, each case may proceed to trial individually.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The U.S. District Judge overseeing the federal Depo-Provera Lawsuit, Judge Casey Rodgers, has called for female attorneys to apply for leadership roles within the multidistrict litigation (MDL).

The MDL was established after studies linked Depo-Provera, a popular birth control shot, to an increased risk of brain tumors, particularly meningiomas.

Given that all plaintiffs in the case are women, Judge Rodgers emphasized the need for adequate female representation in the leadership team.

She stated that while not every position must be filled by a female attorney, it is important that women are properly represented.

The deadline for attorney applications is March 7, 2025, with selected lawyers responsible for handling discovery, managing evidence, and advocating on behalf of all plaintiffs in the MDL.

These cases will not be binding for others in the litigation but are expected to influence settlement discussions, as they will provide valuable insights into how juries may respond to similar claims in the future.

This call for female leadership comes amid backlash from a conservative judicial group, the “Article III Project,” which filed a complaint accusing Judge Rodgers of putting gender above merit.

Despite the complaint, Depo-Provera injury lawyers have strongly criticized the group’s actions, affirming that the focus on gender diversity is crucial to ensure fair representation of the plaintiff group, which consists entirely of women or their families.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The first status conference in the Depo-Provera multidistrict litigation (MDL) is scheduled for Friday, February 21.

A status conference is an initial court meeting where the judge, attorneys, and involved parties discuss case management, procedural timelines, and next steps.

This allows the court to establish deadlines, address preliminary legal issues, and coordinate discovery efforts before moving forward with litigation.

As the case progresses, this conference will help determine the pace and structure of the lawsuits filed against Depo-Provera’s manufacturers.

More updates to follow as proceedings continue.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo Provera MDL has been officially formed and assigned to Judge Rodgers in the Northern District of Florida.

This decision came as a surprise, as plaintiffs sought California and defendants preferred New York, but the JPML panel ultimately selected the Northern District of Florida, citing Judge Rodgers’ mass tort experience.

Judge Rodgers is well known for overseeing the 3M earplug litigation, and with that case winding down, she now takes on another high-profile mass tort that could span the next five years.

While plaintiffs didn’t get their preferred venue, they are optimistic about Rodgers’ ability to efficiently move the litigation toward bellwether trials and resolution.

This decision marks a turning point in the Depo-Provera litigation.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Judicial Panel on Multidistrict Litigation (JPML) held a hearing in Miami, Florida, on January 30, 2025, to discuss consolidating the Depo-Provera cases into a multidistrict litigation (MDL).

While the panel agreed to create an MDL, there was no decision on where to centralize the cases.

At the hearing, the plaintiffs’ attorneys argued that California is the best location, noting that most Depo-Provera lawsuits are already filed there.

They also pointed out that California law allows lawsuits against brand-name drug manufacturers, even when plaintiffs take a generic drug version.

Many of the affected women have undergone brain surgery and could have difficulty traveling, making California a more accessible choice if the case were to go to trial.

Pfizer, the manufacturer of Depo-Provera, wants the litigation to be based in New York, where the company is headquartered.

The company argues that key witnesses and evidence exist and that the lawsuits are spread across multiple states, not just California.

A ruling is expected in the coming weeks.

Attorneys for generic drug manufacturers suggested that filing many early cases in California may have been a legal strategy to influence the location of the MDL.

Once the JPML finalizes a venue, all federal lawsuits related to Depo-Provera will be transferred to that district for pretrial proceedings.

The MDL, designed to streamline the process, promises both sides a more efficient and expedited legal journey, providing reassurance amidst the case’s complexity.

The JPML’s impending decision will be a pivotal factor in shaping the next steps for this ongoing litigation.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The U.S. Judicial Panel on Multidistrict Litigation (JPML) is set to hear arguments on January 30, 2025, about consolidating federal lawsuits related to Depo-Provera into a single multidistrict litigation (MDL). 

These cases, filed against Pfizer and other manufacturers of the birth control shot, claim that the product increases the risk of developing intracranial meningiomas—potentially life-threatening brain tumors.

If approved, the MDL will centralize all current and future lawsuits before one judge to streamline pretrial processes, discovery, and potential early test trials.

Pfizer and generic drug manufacturers have acknowledged the need for an MDL, though they disagree on the appropriate venue for consolidating cases.

The MDL will allow for coordinated pretrial proceedings, but each lawsuit will remain an individual claim.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Patricia Bonilla filed a new class action lawsuit in the U.S. District Court for the Western District of Pennsylvania on January 17.

The lawsuit seeks medical monitoring for women in multiple states who received at least a year of Depo-Provera injections.

Bonilla claims these women face an increased risk of developing brain tumors and should be eligible for ongoing diagnostic testing, such as MRIs and CT scans.

The suit also calls for establishing a nationwide class or state-specific subclasses to address these claims.

Introduced in 1992, Depo-Provera is used by over 70 million women in the U.S.

While Bonilla has not been diagnosed with a brain tumor, she alleges that her use of Depo-Provera over 11 years has created a need for lifelong monitoring.

This medical monitoring lawsuit is separate from the growing number of individual injury claims filed by women who have already developed meningiomas, requiring surgical intervention and facing severe health consequences.

Plaintiffs argue that drug makers withheld crucial information about the risks despite evidence suggesting a potential link between Depo-Provera and brain tumors.

As the legal battle unfolds, the central issue remains whether manufacturers knew of the risks associated with Depo-Provera and failed to provide adequate warnings, leaving thousands of women to bear the potential health and financial consequences.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The growing number of lawsuits alleging a link between Depo Provera and meningioma brain tumors is poised for consolidation under multidistrict litigation (MDL).

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has scheduled a pivotal hearing on January 30, 2025, at the Wilkie D. Ferguson, Jr. U.S. Courthouse in Miami, Florida.

This hearing will determine whether these cases will be consolidated into an MDL, a decision that could significantly shape the litigation’s trajectory.

The location of the MDL, whether in New York or California, is a pivotal factor due to the issue of Innovator’s liability, which affects the rights of the plaintiffs.

Innovator’s liability in product liability law holds a manufacturer or developer responsible for injuries caused by a product, even if it is a new or unapproved design, due to their role in creating and bringing the product to market.

The plaintiffs advocate for the cases to be consolidated in California, where innovator liability laws allow individuals who used generic versions of Depo Provera to pursue legal action against Pfizer.

Notably, 18 of the 22 original MDL motion lawsuits were filed in California.

Conversely, Pfizer is lobbying for the MDL to be located in its home state of New York, where Innovator’s liability does not apply.

Individuals who used generic versions of Depo Provera would likely be barred from participating in the lawsuits if placed in New York.

MDL is the most effective approach for handling complex pharmaceutical cases involving many plaintiffs with diverse injuries.

Unlike a class action lawsuit, MDL centralizes cases for pre-trial proceedings under one federal judge while preserving the individual nature of each claim.

This structure is particularly well-suited to the Depo Provera litigation, as injuries like meningiomas linked to high-dose progestin require individualized evaluations of damages and circumstances.

Once the MDL is established, a streamlined process will allow plaintiffs to file short-form complaints tied to a master complaint.

This will simplify the filing process for attorneys and make it easier for new plaintiffs to join the litigation.

From there, cases are expected to progress toward resolution through individual settlements or a global settlement agreement.

A global settlement plan may include the creation of a compensation fund to address claims collectively.

A settlement matrix would determine payouts, considering each plaintiff’s unique circumstances and injuries, ensuring a fair and equitable process.

This framework is designed to provide efficiency and fairness for victims seeking justice and compensation, instilling confidence as the litigation progresses.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Alongside legal efforts in the United States, Depo-Provera Lawsuits are also being pursued in Australia by women who’ve developed brain tumors after extended use of the contraceptive injection.

A growing class action lawsuit is being pursued against Pfizer, the maker of Depo-Provera, after more Australian women are coming forward with complaints of side effects from using the drug, claiming that they were not informed of the risk.

The British Medical Journal (BMJ) study found that women who used Depo-Provera for more than a year had a five-to-six-fold increased risk of developing meningiomas compared to those who did not use the drug.

This revelation has prompted legal action in several countries, including Australia, where the drug has been used for decades.

Law firms in Australia are recruiting participants for a class action lawsuit against Pfizer, claiming the pharmaceutical giant failed to adequately warn users about the serious risks of brain tumors linked to Depo-Provera.

The class action involves Australian women who received Depo-Provera prescriptions between 1992 and the present, during which time the drug was dispensed more than 3.5 million times across the country.

These women argue that their healthcare providers never informed them about the potential dangers of long-term use of the contraceptive.

Many women reported being prescribed the drug for over a decade, while the medical guidelines recommend a maximum of using the drug for two years.

Australian lawyers and legal professionals in the United States alike are investigating whether Pfizer failed to disclose these risks, leaving millions of women unaware of the potential dangers they were facing.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

University of Plymouth researchers are working to lead a project focused on meningiomas in NF2-related schwannomatosis (NF2-SWN), a condition linked to the loss of the NF2 gene.

Meningiomas, which are typically non-cancerous, can still severely affect patients’ lives.

The Children’s Tumor Foundation funds the project, allowing researchers to create a humanized model to study how human immune cells and meningioma tumors interact.

This is crucial for researchers to develop better therapies for meningioma.

Unlike other tumors, meningiomas have proven to be unaffected by chemotherapy.

While most meningioma can be managed by surgery, recurring or high-level meningioma may need a secondary drug treatment, which causes the need for new and better therapies.

Recent studies have indicated a potential link between Depo Provera, a hormonal birth control for women, and an increased risk of meningiomas.

Over 75 million women worldwide have reported using the drug.

Dr.Liyam Laraba is the head of a team of researchers at the University’s Brian Tumor Research Center of Excellence.

She leads the team in developing the model by transplanting human immune cells into mice, allowing for a more accurate study of potential treatments before clinical trials.

This work is part of the Children’s Tumor Foundation’s NF Preclinical Hub Funding Program, accelerating drug discovery and preclinical testing for neurofibromatosis (NF) disorders.

The program builds on successful initiatives like the NF Preclinical and Therapeutics Consortium to ensure promising therapies reach patients faster.

This research could pave the way for new, more effective treatments for meningiomas and help improve patient outcomes in NF2-SWN.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

As Depo-Provera lawsuits against Pfizer, the birth control drug manufacturer, continue to be filed in federal court, the plaintiffs filed a motion to consolidate all litigations related to the drug before a single judge.

The defense agreed to this proposal but disagreed with the venue’s location and suggested a new venue to centralize the case.

As of December 2024, more than 22 lawsuits had been filed in various U.S. District Courts nationwide.

Six of the 22 pending lawsuits are located in the Northern District of California, which the plaintiffs proposed is the most appropriate venue for centralizing all discovery and pretrial proceedings.

To ease the legal process, the plaintiffs also petitioned to combine these lawsuits into multidistrict litigation (MDL) to avoid repeating the same legal work in different courts.

In a response letter, Pfizer agreed to consolidate the lawsuits into one MDL.

Still, it has opposed the proposed venue and recommended that the cases be transferred to the Southern District of New York, where its corporate headquarters are located.

In their response letter, Pfizer said that the venue’s proximity to their headquarters allows for proximity to key witnesses and evidence, making it a more logical venue for the case.

The Judicial Panel on Multidistrict Litigation (JPML) will decide on the venue and combination of the lawsuits at a hearing on January 30th, 2025.

If approved, all current and future claims will be coordinated before a single judge for pretrial motions. Individual Depo-Provera lawsuits may go to trial if the cases are not settled.

Depo-Provera has been linked to a significantly increased risk of developing meningiomas, a type of brain tumor. Recent studies suggest that women who used the drug face a five-fold greater risk compared to those who did not.

The majority of the lawsuits raise similar claims about Pfizer’s failure to warn women about the potential risks of meningiomas while using the drug, which is why the plaintiffs proposed an MDL.

Women who have suffered from meningiomas after using Depo-Provera are encouraged to explore their legal options as the litigation continues to evolve and grow.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A new lawsuit regarding the birth control drug Depo-Provera was filed in the Eastern District of Louisiana against several major pharmaceutical companies.

The lawsuit claims that the birth control drug led to serious health problems, including intracranial meningioma.

The plaintiff began using quarterly injections of Depo-Provera in 1992, shortly after the FDA approved the drug.

She continued quarterly injections for three to four years.

She experienced many side effects and was eventually diagnosed with intracranial meningioma and paradoxical vocal cord dysfunction in February 2020.

Despite numerous studies showing a link between Depo Provera and meningiomas, the plaintiff claims that the defendants failed to warn her or her healthcare providers about the potential risks of using the drug long-term.

The plaintiff is seeking compensatory damages for medical costs, lost income, and other harm caused by the drug, as well as punitive damages for the defendant’s negligence.

There are more than 22 federal Depo Provera Lawsuits currently pending throughout the US, with at least 18 filed in California.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Women who have used Depo-Provera, an injectable contraceptive manufactured by Pfizer, are filing lawsuits after experiencing severe side effects, including brain tumor diagnoses. 

Meningioma is a type of brain tumor that forms in the membranes surrounding the brain, often causing symptoms such as headaches, vision problems, and seizures.

The lawsuits claim that Pfizer failed to adequately warn users about the potential risks associated with prolonged use of Depo-Provera.

Depo-Provera was approved by the FDA in 1992 as a contraceptive, though its active ingredient, medroxyprogesterone acetate, had been used for other purposes since 1959.

The drug was marketed as a convenient birth control option requiring only four injections per year, targeting busy individuals who sought reliable and low-maintenance contraception.

However, plaintiffs allege that this convenience came with undisclosed health risks.

A March 2024 study conducted in France identified a 5.55-fold increased risk of meningioma among women who used Depo-Provera for one year or longer. 

The study examined over 18,000 women who had undergone surgery for meningiomas between 2009 and 2018.

This research supports claims that prolonged use of Depo-Provera may significantly increase the likelihood of developing this type of tumor.

One plaintiff, identified as T.C. to protect her privacy, shared that she used Depo-Provera for three years and later developed a meningioma.

She reported side effects such as prolonged bleeding, severe headaches, and extreme fatigue during use.

Following her diagnosis, T.C. underwent regular MRIs and treatment to monitor the tumor’s growth, which she describes as a constant source of stress.

Plaintiffs and attorneys are now advocating for greater awareness of Depo-Provera’s risks, encouraging women to seek medical attention if they experience adverse symptoms and legal action if a brain tumor develops.

If you have used the Depo-Provera birth control shot and have suffered brain tumors or other serious health complications, you may be eligible to file a Depo-Provera Lawsuit.

Contact the experienced lawyers at TorHoerman Law for a free consultation.

You can also use the chatbot on this page to get in touch with our experienced team instantly by completing a free case evaluation.

Plaintiffs lawyers have filed a motion to centralize all Depo-Provera Lawsuits into a federal multidistrict litigation (MDL).

Plaintiffs involved in these lawsuits claim that Depo-Provera, a hormonal contraceptive containing medroxyprogesterone acetate, significantly increased their risk of developing these tumors, with recent studies suggesting a fivefold increase in risk for women using the product.

These lawsuits allege that the drug’s manufacturers failed to provide adequate warnings about the potential risks to both users and the medical community.

Many of the affected women have undergone invasive surgeries to address their brain tumors and continue to suffer long-term effects, including vision loss, seizure disorders, and permanent neurological injuries.

On November 26, a motion was filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML), requesting the consolidation of at least 22 lawsuits currently pending in eight district courts across the United States.

The proposed MDL would centralize these cases in the Northern District of California, where six of the lawsuits are already pending.

The plaintiffs argue that all the cases involve nearly identical allegations and similar questions of fact and law, making centralization essential to avoid duplicative discovery, inconsistent rulings, and unnecessary legal costs.

They also emphasize that the size and scope of this litigation are expected to grow rapidly, with many more women likely to file similar claims in the near future.

If the JPML approves the motion, all current and future Depo-Provera lawsuits will be transferred to a single judge for coordinated pretrial proceedings, including discovery and motions.

If you have used the Depo-Provera birth control shot and have suffered brain tumors or other serious health complications, you may be eligible to file a Depo-Provera Lawsuit.

Contact the experienced lawyers at TorHoerman Law for a free consultation.

You can also use the chatbot on this page to get in touch with our experienced team instantly by completing a free case evaluation.

Attorneys representing 22 women have filed federal actions against six manufacturers of Depo-Provera and its generic equivalents.

The motion to consolidate these cases into a multidistrict litigation (MDL) lists Pfizer, Pharmacia & Upjohn Co. LLC, Greenstone LLC, Viatris Inc., Pharmacia LLC, and Prasco LLC as defendants.

If the MDL is approved, these companies could be held liable for producing and marketing a contraceptive alleged to be linked to brain tumor development in multiple women.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Plaintiffs in the Depo-Provera lawsuits have filed a motion with the Judicial Panel on Multidistrict Litigation (JPML) to consolidate the cases into a single multidistrict litigation (MDL).

With 22 cases currently pending, plaintiffs have proposed the U.S. District Court for the Northern District of California as the venue, citing its experience with major MDLs like Roundup.

The next hearing on this matter is scheduled for December 5, 2024, meaning this litigation will not appear on the JPML docket until 2025.

If approved, this could become the first mass tort of the new year.

Plaintiffs argue that the centralized pretrial proceedings provided by an MDL are essential for the complex Depo-Provera litigation, which involves claims of severe health issues such as meningiomas caused by prolonged use of the contraceptive shot.

However, defendants are expected to challenge the consolidation and may seek to move the cases to a District Court in New York instead.

If you have used the Depo-Provera birth control shot and have suffered brain tumors or other serious health complications, you may be eligible to file a Depo-Provera Lawsuit.

Contact the experienced lawyers at TorHoerman Law for a free consultation.

You can also use the chatbot on this page to get in touch with our experienced team instantly by completing a free case evaluation.

On November 26, a motion was filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate at least 22 lawsuits currently pending across eight district courts nationwide.

The proposed multidistrict litigation (MDL) would be centralized in the Northern District of California, where six of the cases have already been filed.

Additionally, plaintiffs anticipate significant growth in the litigation, with many more claims expected to be filed in the coming months.

If the JPML approves the motion, all current and future Depo-Provera lawsuits will be assigned to a single judge for coordinated pretrial proceedings, including discovery and motion hearings.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Recent studies reveal that certain brain tumors associated with Depo-Provera use are inoperable due to their location or their involvement with critical brain structures.

As a result, affected women may need alternative treatments such as radiation therapy, hormone therapy, or participation in clinical trials.

The inability to surgically remove these tumors highlights the serious risks of Depo-Provera use and emphasizes the importance of thorough preoperative imaging to evaluate and plan potential treatment options.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Lawsuits allege that Depo-Provera, a prescription contraceptive drug manufactured by the defendants, caused severe injuries, and scientific studies have linked medroxyprogesterone acetate (MPA), the active ingredient in Depo-Provera, to meningiomas.

A database analysis revealed that injectable MPA increased the likelihood of developing meningiomas by 53%, with the risk escalating with prolonged use.

Additionally, trends in meningioma incidence between 2004 and 2015 indicate significant increases, particularly among females, African Americans, and younger individuals.

Plaintiffs claim the defendants had knowledge for decades but failed to warn patients and healthcare providers in the U.S. of this significant risk.

Unlike in the U.S., the European and Canadian labels for Depo-Provera now include warnings about the potential for meningiomas.

Some Warnings associated with Depo-Provera include:

• Bone Mineral Density Loss: Long-term use (over two years) may cause irreversible bone loss, especially in adolescents and high-risk individuals.
• Thrombosis: Users experiencing thrombosis should discontinue the drug, with further evaluation needed for vision or neurological issues.
• Cancer Risks: Increased risk of breast and cervical cancers has been observed in some users, particularly those with a family history of breast cancer.
• Ectopic Pregnancy: Severe abdominal pain or suspected pregnancy should prompt evaluation for ectopic pregnancy.
• Adverse Reactions: Includes anaphylaxis, weight gain, depression, and irregular bleeding.

If you have used the Depo-Provera birth control shot and have suffered brain tumors or other serious health complications, you may be eligible to file a Depo-Provera Lawsuit.

Contact the experienced lawyers at TorHoerman Law for a free consultation.

You can also use the chatbot on this page to get in touch with our experienced team instantly by completing a free case evaluation.

A 2024 study provides critical support for Depo-Provera lawsuits.

The study found that discontinuing progesterone drugs like Depo-Provera can lead to the regression of meningioma tumors.

This evidence helps causation claims and supports the argument that Depo-Provera increases the risk of meningiomas and that it directly causes tumors in specific plaintiffs.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

For nearly a decade, women in Canada who used Depo-Provera and other DMPA medications have been warned about the potential link between these drugs and meningiomas.

Since at least 2016, Pfizer has included a warning in Canada stating that prolonged use of Depo-Provera may increase the risk of developing intracranial meningiomas.

The Canadian product monograph for Depo-Provera explicitly warns: “Meningiomas have been reported following long-term administration of progestins, including medroxyprogesterone acetate (MPA).”

Additionally, the accompanying drug information advises physicians to exercise caution when prescribing Depo-Provera to patients with a history of meningiomas and to discontinue its use immediately if a patient develops a meningioma.

In contrast, Pfizer has not included similar warnings or guidance about meningiomas in the prescribing information for Depo-Provera in the United States.

As a result, many U.S. women are only now becoming aware of the potential association between Depo-Provera and brain tumors.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Settlements in Depo-Provera lawsuits have the potential to be significantly higher than those seen in comparable mass tort cases. Several factors contribute to this outlook.

A study indicates a 5.5x increase in the risk of brain tumors (meningiomas) among Depo-Provera users.

This is one of the highest relative risk increases documented in large-scale litigation.

Brain tumors are life-altering and dramatic injuries, which often lead to higher settlement values due to their profound impact on plaintiffs’ lives.

According to CDC data:

From 2017 to 2019, about 2% of women aged 15 to 49 used Depo-Provera.

Usage was higher in previous decades: 4.5% of women aged 15 to 44 had used it by 1995, and 23% between 2006 and 2010.

Estimates suggest that several million women used the drug annually during its peak years.

This means approximately 1,300 meningioma cases per year, with the drug being in use for over 32 years.

Overall, between 5,000 and 30,000 potential lawsuits could arise. 

However, not all eligible plaintiffs may choose to file claims, which could further enhance settlement values.

Given the strength of the evidence, severity of injuries, and manageable plaintiff numbers, average settlements are expected to exceed $100,000 per case, with some plaintiffs receiving significantly higher amounts depending on the circumstances.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A California woman, Anjanna Lawson, has filed a lawsuit against Pfizer and other associated companies after being diagnosed with an intracranial meningioma.

Lawson began using Depo-Provera injections at the age of 16 and continued until September 2024.

In July 2023, she underwent a right pterional craniotomy to remove the tumor. However, a residual tumor was detected in early 2024, requiring five sessions of stereotactic radiosurgery.

Despite these treatments, the tumor persists, leaving Lawson with debilitating symptoms, including vision loss, facial spasms, and a burning sensation in her face.

The lawsuit targets Pfizer, Inc., Viatris, Inc., Greenstone, LLC, Prasco, LLC, Pharmacia & Upjohn LLC, and Pharmacia, LLC. Lawson alleges that these companies failed to provide sufficient warnings about the risk of developing intracranial meningiomas associated with Depo-Provera use.

Key Details of Anjanna Lawson’s Case:

• Plaintiff: Anjanna Lawson, California resident.
• Defendants: Pfizer, Inc., Viatris, Inc., Greenstone, LLC, Prasco, LLC, Pharmacia & Upjohn LLC, and Pharmacia, LLC.
• Allegations: Failure to warn users about the risks of intracranial meningiomas linked to Depo-Provera.
• Symptoms: Vision loss, facial spasms, and facial burning sensation due to an unresolved tumor.
• Treatment: Right pterional craniotomy followed by stereotactic radiosurgery.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Depo-Provera Lawsuits continue to be filed in federal courts, with expectations of more than 30 cases by the end of November.

Filings are particularly concentrated in the Northern District of California and the Southern District of Texas.

The upcoming Judicial Panel on Multidistrict Litigation (JPML) hearing, scheduled for December 5, 2024, will likely address potential consolidation. 

However, an official multidistrict litigation (MDL) is not anticipated before the end of the year.

An MDL is typically created when 25 or more related cases are pending in various federal courts, addressing common issues and involving similar defendants.

This threshold is expected to be met in the Depo-Provera lawsuits.

Although plaintiffs are likely to seek consolidation in California, defendants may oppose and recommend New York as the venue for coordination.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly. 

A new lawsuit against the makers of Depo-Provera has been filed in the U.S. District Court for the Central District of California, alleging that the popular birth control shot led to the development of a meningioma brain tumor in a California woman after nearly 25 years of use.

The plaintiff is suing Pfizer, Viatris, Greenstone, Prasco, and Pharmacia and Upjohn, asserting that the companies failed to provide adequate warnings in the U.S. about the potential risk of brain tumors linked to Depo-Provera, a risk noted on Canadian labels since 2015.

The lawsuit claims that Jones began receiving Depo-Provera injections in 2000, with regular injections totaling 91 over her treatment period.

In 2020, after experiencing symptoms like headaches, blurred vision, vertigo, and ear itching, she was diagnosed with a calcified meningioma brain tumor, which later grew in size.

Due to the calcified state of the tumor, surgical removal has been deemed too dangerous, leaving Jones to endure chronic pain and other symptoms.

The complaint alleges that Pfizer and associated companies failed to thoroughly investigate and warn about the risks of long-term Depo-Provera use, which includes potential links to meningioma.

The lawsuit is part of a growing number of Depo-Provera lawsuits filed across the U.S.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly.

Pfizer and its co-defendants are facing nine allegations in a federal lawsuit filed in California.

The charges include Failure to Warn, Design Defect, Negligence, Negligent Failure to Warn, Negligent Design Defect, Negligent Misrepresentation, Fraudulent Misrepresentation, Breach of Express Warranty, and Breach of Implied Warranty.

The lawsuit accuses Pfizer and its co-defendants of knowingly designing, manufacturing, and marketing a product that could lead to intracranial meningiomas without providing sufficient warnings to consumers.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The ongoing Depo-Provera Lawsuits have brought attention to legal nuances regarding the statute of limitations in these cases.

There are two main reasons why the statute of limitations should not significantly affect individuals filing lawsuits for Depo-Provera-related injuries at this time.

First, the “discovery rule” applies across states and can extend the statute of limitations.

The principle delays the deadline for filing a lawsuit until the injured party becomes aware of the injury and its connection to a specific cause.

In the case of Depo-Provera, recent scientific studies have revealed a potential link between the drug and brain tumors, an association not widely known before these studies.

Given the recent emergence of this evidence, plaintiffs could not reasonably have been expected to link their conditions to Depo-Provera until now.

Additionally, the doctrine of fraudulent concealment may also apply.

This doctrine states if a defendant intentionally conceals crucial safety information, the statute of limitations can be paused.

Plaintiffs allege that Depo-Provera’s manufacturers actively suppressed knowledge of the drug’s risks by manipulating safety warnings and product labeling, making it challenging for consumers to understand the potential link between Depo-Provera and meningiomas.

The alleged concealment of safety information means plaintiffs may argue they were prevented from learning of these risks, effectively extending the timeline for filing lawsuits.

This combination of the discovery rule and fraudulent concealment may give plaintiffs a strong basis to counter statute of limitations concerns in the Depo-Provera Lawsuit, allowing time to pursue claims linked to their injuries.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly.

A French study has identified a connection between Depo-Provera injections and meningiomas, tumors that develop from the protective membranes surrounding the brain and spinal cord.

Common symptoms of meningiomas include Headaches, Vision changes, Seizures, Memory loss, and Dizziness

Additional research is necessary to determine why Depo-Provera may contribute to an increased risk of tumor growth.

Given that 74 million women worldwide have used the drug, the potential scope of this litigation could be substantial.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A 2020 review of 47 meningioma lawsuits has drawn the attention of legal experts investigating claims involving women who used Depo-Provera.

The analysis revealed that failure to diagnose was the primary issue in 68.1% of these cases.

Should a connection between Depo-Provera and an increased risk of meningiomas be established, legal analysts predict that settlement amounts could reach several hundred thousand dollars.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Depo-Provera encountered numerous FDA rejections during the 1970s and 1980s before ultimately receiving approval in 1992.

Since then, the contraceptive has been linked to decreased bone density and notable side effects after discontinuation.

Recent studies have raised concerns about a possible connection between Depo-Provera and brain tumors, further amplifying the health risks associated with its use.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly.